Aug. 7, 2024
The Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services recently announced the Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. GLIDE aims to develop physical, pharmacologic, gene and cell-based therapeutic interventions to treat primary and rare lymphatic disease (LD) and chronic conditions complicated by lymphatic dysfunction.

GLIDE’s goals are spread across two technical areas for developing new physical and pharmacological therapies targeting abnormal lymphatic structure and function. Through advances in biomaterials, interventional radiology (IR) and minimally invasive surgical approaches and imaging, GLIDE will accelerate therapeutic options in compression, IR, microsurgery, and other minimally invasive technologies. Additionally, GLIDE will support the development of targeted pharmacologic gene and cell therapies that directly target mechanisms of lymphatic dysfunction to modulate tissue contractility and vessel growth.

For more information on the GLIDE program, ARPA-H will host a Hybrid Proposers' Day Sept. 17.

For more information about American College of Radiology® (ACR®) collaborations with ARPA-H, contact Katie Grady, ACR Government Affairs Director.

Related ACR News

  • ACR Advises Changes to Washington State PAD Report

    ACR urged the WA State Health Technology Clinical Committee to not act on the draft report that would limit coverage of endovascular procedures for PAD.

    Read more
  • ACR Releases Impact Tables for 2026 MPFS Proposed Rule

    The tables cover specific proposed changes in reimbursement rates between 2025 and 2026 for each CPT® code.

    Read more
  • Take Action: Contact Your US Senators to Cosponsor ROOT Act

    Support the ROOT Act—Senate cosponsors needed to fix CMS issues with imaging AUC under PAMA. College member advocacy is key.

    Read more